Device Women'S Health

Supris

Payments companies reported to CMS as associated with Supris. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$14Kassociated payments (2023-2025)
156clinicians with associated payments
2companies reporting

By year

2023 $3,415
2024 $2,902
2025 $8,000

Payments reported as associated with Supris, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) $4,467
Urology $4,095
Obstetrics & Gynecology $3,275
Nurse Practitioner $480
Gynecology $476
Urogynecology and Reconstructive Pelvic Surgery (Urology) $423

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Supris

These are the largest totals companies reported as associated with Supris. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Arash Rahi Coconut Creek, FL Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) $947.10
Robert Asgharian El Paso, TX Obstetrics & Gynecology $497.75
Yoko Bean Los Angeles, CA Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) $443.13
Nicole Szell Largo, FL Urogynecology and Reconstructive Pelvic Surgery (Urology) $397.38
Lindsey Jackson Boerne, TX Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) $331.60
Keri Rowley Seattle, WA $255.60
Douglas Miyazaki Winston Salem, NC Obstetrics & Gynecology $248.04
John Smith Winston Salem, NC Urology $248.03
Costas Apostolis Strongsville, OH Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) $244.20
Glenn Gangi Mullins, SC Urology $231.00

Prescribed Supris?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.